Detection of PD-L1 in circulating tumor cells of non-small cell lung cancer and its clinical applications
10.3760/cma.j.cn371439-20250312-00110
- VernacularTitle:非小细胞肺癌循环肿瘤细胞PD-L1检测及临床应用
- Author:
Ziyan SONG
1
;
Wenjing ZHANG
;
Zhendan WANG
;
Zhikun ZHAO
;
Ying MA
;
Sheng LI
Author Information
1. 山东第一医科大学（山东省医学科学院）临床与基础医学院，济南 250117
- Keywords:
Carcinoma, non-small-cell lung;
Neoplastic cells, circulating;
B7-H1 antigen;
Detection techniques
- From:
Journal of International Oncology
2025;52(10):641-645
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer (NSCLC) is a malignant tumor with a high global incidence rate, accounting for about 10.54% of all new cancer cases and posing a serious threat to human health. Due to significant individual variations in the efficacy of immunotherapy among NSCLC patients, it is necessary to identify accurate detection indicators to screen appropriate populations, monitor treatment efficacy, and assist in prognosis assessment. Programmed death-ligand 1 (PD-L1), as an immunosuppressive molecule expressed on the surface of tumor cells and various immune cell membranes, can serve as a "companion diagnostic" or "supplementary diagnostic" tool to guide clinical treatment decisions for metastatic NSCLC patients. Given that tumor tissue PD-L1 testing is an invasive procedure and its reliability is still under debate, the assessment of PD-L1 expression via liquid biopsies, such as circulating tumor cells, will play a significant role in predicting treatment response and prognosis in NSCLC patients.
